ImpediMed Future Growth

Future criteria checks 2/6

ImpediMed is forecast to grow earnings and revenue by 38.1% and 39.8% per annum respectively. EPS is expected to grow by 44% per annum. Return on equity is forecast to be -11.9% in 3 years.

Key information

38.1%

Earnings growth rate

44.0%

EPS growth rate

Medical Equipment earnings growth	16.6%
Revenue growth rate	39.8%
Future return on equity	-11.9%
Analyst coverage	Low
Last updated	01 May 2024

Recent future growth updates

Recent updates

Earnings and Revenue Growth Forecasts

CHIA:IPD - Analysts future estimates and past financials data (AUD Millions)
Date	Revenue	Earnings	Free Cash Flow	Cash from Op	Avg. No. Analysts
6/30/2026	32	-5	-1	3	1
6/30/2025	19	-14	-17	-13	2
6/30/2024	11	-21	-23	-18	2
12/31/2023	10	-19	-18	-13	N/A
9/30/2023	11	-20	-21	-15	N/A
6/30/2023	11	-21	-24	-18	N/A
3/31/2023	11	-21	-25	-20	N/A
12/31/2022	11	-22	-27	-22	N/A
9/30/2022	11	-21	-24	-19	N/A
6/30/2022	11	-20	-21	-16	N/A
3/31/2022	10	-20	-19	-14	N/A
12/31/2021	10	-19	-17	-13	N/A
9/30/2021	9	-20	-16	-13	N/A
6/30/2021	8	-21	-16	-13	N/A
3/31/2021	7	-20	-17	-15	N/A
12/31/2020	6	-19	-18	-16	N/A
9/30/2020	6	-20	-20	-18	N/A
6/30/2020	6	-21	-21	-19	N/A
12/31/2019	5	-25	-22	-20	N/A
9/30/2019	5	-24	-22	-20	N/A
6/30/2019	4	-24	-22	-20	N/A
12/31/2018	4	-25	-23	-21	N/A
9/30/2018	3	-26	-24	-22	N/A
6/30/2018	3	-27	-25	-23	N/A
3/31/2018	4	-28	N/A	N/A	N/A
12/31/2017	4	-28	-26	-26	N/A
9/30/2017	5	-28	N/A	-26	N/A
6/30/2017	6	-28	N/A	-26	N/A
3/31/2017	6	-28	N/A	-25	N/A
12/31/2016	6	-29	N/A	-25	N/A
9/30/2016	6	-27	N/A	-24	N/A
6/30/2016	6	-26	N/A	-22	N/A
3/31/2016	6	-23	N/A	-19	N/A
12/31/2015	5	-20	N/A	-16	N/A
9/30/2015	5	-17	N/A	-13	N/A
6/30/2015	5	-15	N/A	-11	N/A
3/31/2015	4	-13	N/A	-9	N/A
12/31/2014	4	-10	N/A	-8	N/A
9/30/2014	4	-9	N/A	-7	N/A
6/30/2014	4	-8	N/A	-7	N/A
3/31/2014	3	-7	N/A	-6	N/A
12/31/2013	3	-7	N/A	-6	N/A
9/30/2013	3	-8	N/A	-7	N/A
6/30/2013	3	-8	N/A	-8	N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: IPD is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: IPD is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: IPD is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: IPD's revenue (39.8% per year) is forecast to grow faster than the Australian market (5.2% per year).

High Growth Revenue: IPD's revenue (39.8% per year) is forecast to grow faster than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: IPD is forecast to be unprofitable in 3 years.

ImpediMed Future Growth

Future criteria checks 2/6

Key information

Recent future growth updates

No longer forecast to breakeven

No longer forecast to breakeven

No longer forecast to breakeven

No longer forecast to breakeven

Forecast to breakeven in 2024

Recent updates

ImpediMed Limited to Report Q3, 2024 Results on Apr 30, 2024

ImpediMed to Present Chronic Breast Cancer-Related Lymphedema Study Results at American Society of Breast Surgeons Annual Meeting

Independent Non-Executive Director recently bought AU$100k worth of stock

Independent Non-Executive Director recently bought AU$90k worth of stock

No longer forecast to breakeven

High number of new and inexperienced directors

ImpediMed Limited to Report First Half, 2024 Results on Feb 27, 2024

Independent Non-Executive Director recently bought AU$135k worth of stock

ImpediMed Limited Announces CFO Changes

ImpediMed Limited to Report Q1, 2024 Results on Oct 31, 2023

ImpediMed Limited, Annual General Meeting, Nov 30, 2023

High number of new directors

ImpediMed Limited Announce the Appointment of Steven Chen as Chief Medical Officer

Full year 2023 earnings released: AU$0.01 loss per share (vs AU$0.012 loss in FY 2022)

ImpediMed Limited, Annual General Meeting, Sep 28, 2023

ImpediMed Limited to Report Q4, 2023 Results on Jul 24, 2023

ImpediMed Limited Appoints Daniel Sharp as Director

Executive Director recently bought AU$144k worth of stock

Independent Non-Executive Chairman recently bought AU$82k worth of stock

No longer forecast to breakeven

MD, CEO & Director recently bought AU$52k worth of stock

MD, CEO & Director recently bought AU$54k worth of stock

MD, CEO & Director recently bought AU$64k worth of stock

First half 2023 earnings released: AU$0.01 loss per share (vs AU$0.006 loss in 1H 2022)

ImpediMed Limited to Report Q2, 2023 Results on Jan 30, 2023

ImpediMed Limited Presents New Data at 2022 San Antonio Breast Cancer Symposium Shows Early Detection Using L-Dex and Intervention Improves Lymphedema Progression-Free Survival

Impedimed Limited Announces CEO Changes

ImpediMed Limited Announces Management Changes

Less than half of directors are independent

Executive Director & Interim CEO recently bought AU$164k worth of stock

Less than half of directors are independent

ImpediMed Limited Announces Current Data Support Early Detection and Intervention to Reduce Rates of Breast Cancer Related Lymphedema

ImpediMed Limited to Report Q1, 2023 Results on Oct 19, 2022

ImpediMed Expands Use of SOZO in Leading Cancer Centers Focused on Reducing the Impact of Lymphedema after Breast Cancer

ImpediMed Announces U.S. Launch of Lymphedema Prevention Program with GenesisCare a Global Organization Dedicated to Care of Cancer Patients

ImpediMed Limited Announces Board Changes

Full year 2022 earnings released: AU$0.01 loss per share (vs AU$0.017 loss in FY 2021)

ImpediMed Limited, Annual General Meeting, Oct 26, 2022

Less than half of directors are independent

ImpediMed Limited Announces Executive Changes

ImpediMed Limited Announces Resignation of Richard Carreon as Managing Director

ImpediMed Limited Announces Release of the New Version 4.1 Software for the SOZO Digital Health Platform

No longer forecast to breakeven

ImpediMed Limited to Report Q3, 2022 Results on Apr 28, 2022

New Bone Data Showing Strong Correlation Between ImpediMed's SOZO and DXA in Cancer Patients Presented At 39Th Annual Miami Breast Cancer Conference

No longer forecast to breakeven

First half 2022 earnings: EPS in line with expectations, revenues disappoint

Now 22% undervalued

Forecast to breakeven in 2024

FDA Grants Breakthrough Device Designation for ImpediMed's SOZO Digital Health Platform for Renal Failure

Full year 2021 earnings released: AU$0.02 loss per share (vs AU$0.036 loss in FY 2020)

Impedimed Announces Next Generation of Sozo® Digital Health Platform Software

ImpediMed Limited Announces Official Release of SOZO Version 4.0 Software

First half 2021 earnings released: AU$0.01 loss per share (vs AU$0.026 loss in 1H 2020)

ImpediMed Limited to Report Q2, 2021 Results on Jan 28, 2021

ImpediMed Limited Announces PREVENT Trial Finishes ­- Final Patient Completes Follow-Up

Impedimed Limited Announces the Publication of A New Study Demonstrating That the Company's Lymphedema Prevention Program

ImpediMed Limited Secures First Commercial Heart Failure Sales

ImpediMed Limited Announces NSW Health Further Expands Lymphoedema Prevention Program

AstraZeneca Selects SOZO for Second Large Renal Trial

HFSA Poster Supports HF-Dex in the Management of HF Patients

Impedimed Limited Announces Collaboration with the Live Today Foundation to Increase Awareness and Access to Care for Cancer Patients At Risk or Suffering from Lymphedema

Impedimed Limited Announces Contract Valued at over AUD 2 Million for its SOZO Digital Health Platform to Be Used in Clinical Trial Being Conducted for AstraZeneca

ImpediMed Limited(ASX:IPD) dropped from S&P/ASX Emerging Companies Index

ImpediMed Limited Auditor Raises 'Going Concern' Doubt

Earnings released

ImpediMed Limited to Report Q4, 2020 Results on Jul 28, 2020

ImpediMed Limited announced that it has received AUD 0.227339 million in funding

Earnings and Revenue Growth Forecasts

Analyst Future Growth Forecasts

ImpediMed Limited Announces PREVENT Trial Finishes - Final Patient Completes Follow-Up